viru
known
caus
aid
initi
name
lymphadenopathyassoci
viru
lav
may
april
announc
viru
known
caus
aid
isol
name
human
tcell
leukemia
virusiii
htlviii
thought
lav
htlviii
could
viru
march
unit
state
food
drug
administr
fda
licens
first
blood
test
aid
creat
abbott
laboratori
identifi
possibl
antibodi
hiv
name
hiv
human
immunodefici
viru
given
intern
commiss
virolog
nomenclatur
may
natur
play
import
role
gener
uniqu
drug
prototyp
anticanc
agent
deriv
natur
sourc
around
earth
biospher
repres
marin
ecosystem
henc
marin
sourc
invalu
sourc
discoveri
new
compound
treatment
diseas
like
aid
cancer
exampl
three
compound
spongosin
spongothymidin
spongouridin
isol
cryptotethia
crypta
caribbean
marin
spong
compound
first
report
bioactiv
nucleosid
isol
marin
speci
first
anticanc
lead
marin
organ
cytosin
arabinosid
arac
synthet
deriv
develop
spong
natur
product
prototyp
synthes
arac
first
report
walwick
lee
first
report
synthes
araa
vidarabin
araa
use
antivir
agent
treatment
herp
simplex
viru
type
type
infect
mani
year
although
acyclovir
wide
prescrib
arac
use
treatment
acut
myelocyt
leukaemia
hodgkin
lymphoma
mention
drug
first
fdaapprov
marinederiv
product
use
treatment
diseas
also
basi
synthesi
develop
zidovudin
azt
zdv
initi
test
cancer
antibacteri
later
approv
hiv
sinc
extens
investig
taken
place
treatment
variou
diseas
marin
sourc
well
develop
nucleosid
scheme
resist
azt
year
combin
therapi
develop
becam
success
util
azt
ddc
mani
case
occur
peopl
resist
azt
june
fda
approv
anoth
nrti
stavudin
also
shown
transmiss
hiv
mother
child
could
reduc
use
azt
pregnanc
recent
exampl
correspond
includ
antiretrovir
therapi
art
given
h
birth
infant
born
infect
art
continu
detect
dna
rna
discontinu
therapi
child
reach
month
age
child
found
undetect
antibodi
suggest
earli
art
may
help
alter
longterm
persist
infect
howev
child
later
found
viral
posit
two
year
art
suggest
continu
challeng
control
hiv
infect
proteas
inhibitor
saquinavir
inviras
approv
fda
year
novemb
fda
approv
nrti
lamivudin
new
nonnucleosid
revers
transcriptas
inhibitor
nnrti
viramun
also
known
nevirapin
approv
fda
year
viral
load
test
call
amplicor
monitor
test
introduc
test
gave
clinician
abil
document
progress
diseas
septemb
fda
approv
nrti
combivir
combin
lamivudin
zidovudin
two
clinic
trial
prove
combin
azt
ddc
much
effect
prolong
life
delay
diseas
compar
azt
use
alon
abacavir
anoth
nrti
approv
fda
decemb
year
origin
sourc
hiv
found
pan
troglodyt
type
chimpanze
common
west
central
africa
hypothes
viru
enter
human
popul
hunter
expos
infect
blood
chimpanze
spermicid
proven
ineffect
microbicid
reduct
transmiss
hiv
sex
first
hiv
vaccin
trial
took
place
oxford
uk
septemb
indian
compani
cipla
offer
aid
drug
low
per
day
provid
guidelin
antiretrovir
drug
also
releas
list
drug
could
use
aid
fuzeon
fusion
inhibitor
also
came
exist
inject
drug
bring
forth
new
campaign
control
spread
hiv
call
abc
short
abstin
faith
condom
use
great
mission
rescu
initi
former
unit
state
presid
georg
w
bush
combat
aid
caribbean
africa
year
vaxgen
made
announc
regard
failur
aid
vaccin
reduc
hiv
infect
rate
novemb
vaccin
found
failur
clinic
trial
thailand
march
fda
approv
new
type
antihiv
drug
prevent
hiv
entri
human
cell
fuzeon
also
known
enfuvirtid
first
drug
classifi
fusion
inhibitor
fuzeon
avail
form
inject
could
use
combin
therapi
patient
resist
antiretrovir
drug
unnatur
lnucleosid
lamivudin
emtricitabin
becam
commerci
avail
revolution
treatment
hiv
hepat
b
viru
hbv
sinc
drug
part
mani
highli
effect
fixeddos
combin
juli
fda
approv
emtricitabin
decemb
world
aid
day
declar
three
five
campaign
provid
antiretrovir
treatment
three
million
peopl
resourcepoor
countri
anoth
similar
polici
call
four
free
one
care
declar
chines
govern
includ
mani
servic
provid
free
antiretrovir
agent
poor
rural
commun
free
test
counsel
free
drug
prevent
transmiss
mother
child
free
school
orphan
aidsrel
death
proper
care
econom
help
peopl
afflict
hiv
aid
first
time
histori
global
fund
stop
fund
scheme
fight
aid
march
first
oral
fluid
rapid
test
hiv
approv
unit
state
fda
presid
georg
w
bush
pepfar
also
known
presid
emerg
plan
aid
relief
fulli
implement
june
design
focu
countri
africa
well
haiti
guyana
vietnam
januari
fda
approv
antiretrovir
agent
copackag
drug
regimen
lamivudin
zidovudin
nevirapin
made
aspen
pharmacar
south
african
compani
mark
first
hiv
drug
regimen
approv
nonunit
state
base
pharmaceut
compani
mileston
repres
huge
turn
point
africa
provid
cheaper
pharmaceut
treatment
septemb
patent
period
azt
came
end
allow
mani
pharmaceut
compani
produc
drug
sell
greatli
reduc
price
first
time
pill
could
taken
day
treatment
infect
approv
unit
state
wide
use
firstlin
treatment
atripla
includ
combin
three
drug
emtriva
emtricitabin
sustiva
efavirenz
viread
tenofovir
disoproxil
fumar
tdf
fda
approv
two
new
drug
raltegravir
isentress
maraviroc
selzentri
could
use
patient
resist
class
antihiv
drug
octob
initi
result
vaccin
develop
merck
pharmaceut
compani
found
ineffect
result
termin
trial
conduct
hundr
particip
american
fund
program
pepfar
renew
treatment
hivaid
malaria
tuberculosi
year
presid
obama
promis
lift
travel
ban
implement
year
prevent
peopl
infect
hivaid
enter
unit
state
final
januari
ban
lift
result
microbicid
trial
caprisa
highlight
biannual
intern
aid
confer
juli
accord
phase
iib
trial
result
found
safe
effect
use
antiretroviralbas
gel
hivneg
women
reduc
risk
acquir
infect
octob
new
drug
applic
singledrug
regimen
also
known
quad
pill
submit
gilead
scienc
inc
includ
elvitegravir
cobicistat
emtricitabin
tdf
truvada
fixeddos
combin
emtricitabin
tenofovir
disoproxil
fumar
approv
fda
juli
preexposur
prophylaxi
prep
hiv
manufactur
gilead
dolutegravir
tivicay
approv
fda
august
market
viiv
healthcar
manufactur
gsk
use
treatmentexperienc
patient
histori
hivaid
outlin
concept
hivaid
drug
current
avail
market
use
prevent
replic
viru
bodi
extend
lifetim
peopl
hivposit
year
cure
erad
elimin
hiv
complet
yet
identifi
figur
viru
particl
spheric
diamet
one
tenthousandth
millimet
viral
envelop
outer
coat
includ
two
layer
lipid
taken
human
membran
viru
new
viru
form
cell
throughout
viral
envelop
protein
includ
copi
complex
protein
call
env
embed
surfac
viru
spike
env
copi
call
virion
env
includ
glycoprotein
cap
contain
three
molecul
glycoprotein
stem
three
molecul
two
protein
adher
structur
viral
envelop
research
concern
hiv
vaccin
mainli
focus
protein
bulletshap
capsid
core
present
insid
viral
envelop
made
copi
viral
protein
surround
capsid
two
singlestrand
rna
includ
complet
copi
viral
gene
gag
pol
env
three
structur
gene
carri
inform
necessari
format
structur
protein
new
viral
particl
similarli
tat
nef
vif
vpr
vpu
rev
six
regulatori
gene
respons
control
viru
regard
infect
host
produc
diseas
rna
sequenc
call
long
termin
repeat
ltr
present
end
strand
viral
rna
region
control
product
new
virus
nucleocapsid
protein
present
core
matrix
protein
present
core
envelop
viru
also
requir
three
enzym
complet
replic
cycl
revers
transcriptas
proteas
integras
figur
hiv
reproduc
human
replic
cycl
occur
six
stage
begin
bind
receptor
along
one
coreceptor
among
two
tlymphocyt
surfac
lead
fusion
viru
host
cell
therebi
lead
releas
viral
rna
cell
call
bind
fusion
stage
stage
ii
call
revers
transcript
stage
revers
transcriptas
enzym
present
viru
convert
singlestrand
viral
rna
doublestrand
viral
dna
stage
iii
integr
stage
viral
dna
form
stage
ii
enter
host
cell
nucleu
incorpor
viral
dna
within
host
cell
dna
viral
enzym
integras
integr
viral
dna
call
proviru
could
reproduc
copi
remain
inact
mani
year
fourth
stage
transcript
proviru
produc
copi
viral
genom
well
messeng
rna
mrna
shorter
strand
rna
help
host
rna
clinic
symptom
pathogenesi
hiv
hcv
similar
polymeras
hiv
includ
rnadepend
dna
polymeras
also
known
revers
transcriptas
hcv
includ
rnadepend
rna
polymeras
refer
rna
replicas
wherea
hiv
proteas
aspartyl
proteas
hcv
proteas
serin
proteas
drug
belong
differ
categori
use
treatment
hiv
hcv
mention
nucleotid
revers
transcriptas
inhibitor
ntrti
approv
treatment
hiv
tdf
viread
although
current
approv
nucleosid
analogu
requir
phosphoryl
inhibit
hiv
polymeras
nonnucleosid
revers
transcriptas
inhibitor
nnrti
use
treatment
hiv
includ
nevirapin
rilpivirin
edur
etravirin
efavirenz
delavirdin
figur
known
nucleosid
rna
replicas
inhibitor
nrri
possess
antihcv
activ
vitro
known
date
includ
valopicitabin
possess
antihcv
activ
presenc
methyl
group
fluorin
group
posit
azido
group
posit
essenti
new
nucleosid
deriv
contain
substitut
singl
molecul
would
area
explor
antihcv
activ
figur
sofosbuvir
previous
name
uridin
nucleotid
analogu
current
phase
trial
treatment
hcv
infect
select
inhibitor
hcv
polymeras
combin
pegyl
interferon
ribavirin
also
tri
efficaci
sofosbuvir
treat
hcv
although
interferonfre
treatment
popular
eg
use
sofosbuvir
inhibitor
ledipasvir
combin
call
harvoni
approv
fda
octob
simeprevir
secondgener
macrocycl
compound
hcv
proteas
inhibitor
bind
noncoval
hcv
proteas
approv
fda
novemb
daclatasvir
replic
complex
inhibitor
manufactur
bristolmy
squibb
phase
iii
clinic
trial
combin
sofosbuvir
treatment
hcv
use
combin
antivir
drug
treatment
hcv
declin
fda
novemb
fda
approv
viekira
pak
decemb
combin
ombitasvir
paritaprevir
ritonavir
tablet
copack
dasabuvir
tablet
treatment
chronic
hcv
infect
figur
proteas
hiv
hcv
attract
drug
target
viral
proteas
inhibitor
use
treatment
hiv
includ
amprenavir
indinavir
lopinavir
fosamprenavir
nelfinavir
darunavir
tipranavir
atazanavir
anoth
proteas
inhibitor
brecanavir
could
use
combin
ritonavir
treatment
person
figur
hcv
serin
proteas
inhibitor
includ
boceprevir
telaprevir
ciluprevir
figur
drug
still
clinic
trial
includ
entri
inhibitor
pro
ibalizumab
cenicriviroc
integras
inhibitor
elvitegravir
dolutegravir
matur
inhibitor
vivecon
nnrti
like
lersivirin
dapivirin
nrti
like
kp
apricitabin
elvucitabin
racivir
festinavir
alovudin
amdoxovir
figur
c
scheme
bevirimat
matur
inhibitor
dexelvucitabin
reverset
nrti
exampl
discontinu
drug
undergon
clinic
trial
figur
scheme
schemat
represent
drug
act
variou
stage
viral
replic
cycl
shown
figur
pneumonia
second
lead
caus
death
global
around
million
case
annual
unit
state
proper
medic
complet
treat
diseas
state
exist
pneumonia
occur
continuum
acut
influenza
syndrom
caus
viru
alon
term
primari
infect
could
caus
mix
infect
virus
bacteria
term
secondari
infect
often
difficult
identifi
etiolog
pathogen
mani
differ
bacteri
strain
streptococcu
pneumonia
mycoplasma
pneumonia
chlamydia
pneumonia
haemophilu
influenza
legionella
pneumophila
common
caus
death
due
pneumonia
mainli
secondari
bacteri
infect
due
one
sever
mention
strain
lead
combin
bacterialvir
postinfluenza
pneumonia
influenza
virus
belong
famili
orthomyxovirida
envelop
lipid
neg
sens
singlestrand
segment
rna
virus
exist
three
form
influenza
b
c
influenza
viru
known
infect
mammal
includ
hors
pig
bird
wherea
influenza
b
c
known
infect
human
intub
infect
airborn
transmiss
incub
period
h
viral
shed
begin
h
absenc
antivir
environ
follow
inhal
viru
deposit
epithelium
respiratori
tract
becom
attach
ciliat
epitheli
cell
surfac
hemagglutinin
viral
particl
elimin
secret
iga
antibodi
mucociliari
clearanc
viral
particl
invad
respiratori
epitheli
cell
continu
viral
replic
newli
form
virus
infect
epitheli
cell
larg
number
elimin
synthesi
critic
protein
lead
death
host
cell
variou
antivir
drug
use
treatment
influenza
includ
neuraminidas
inhibitor
includ
oseltamivir
zanamivir
adamantan
drug
includ
amantadin
rimantadin
antivir
drug
reduc
risk
complic
vaccin
mean
control
prevent
influenza
figur
hepat
b
third
lead
caus
death
global
also
first
major
viral
diseas
peopl
chronic
infect
current
million
peopl
carrier
hepat
b
increas
risk
develop
hepat
decompens
hepatocellular
carcinoma
cirrhosi
hepat
b
chronic
necroinflammatori
liver
diseas
caus
hepat
b
viru
hbv
could
divid
hbeag
posit
neg
chronic
hepat
b
hbv
smallest
known
dna
viru
hepadnaviru
possess
base
genom
genom
consist
circular
dna
partli
doublestrand
one
strand
term
minu
almost
complet
circular
includ
overlap
gene
encod
replic
protein
like
polymeras
x
structur
protein
like
surfac
core
pre
term
plu
short
vari
length
figur
enh
enh
ii
two
enhanc
element
enh
function
compet
hepatocyt
tissuespecif
enh
ii
act
surfac
gene
promot
stimul
transcript
activ
hbv
nucleocapsid
nm
sphere
bear
core
antigen
along
hbv
e
antigen
viral
dna
dna
polymeras
nucleocapsid
envelop
hbv
surfac
antigen
hbsag
determin
addit
determin
nucleocapsid
also
carri
one
two
pair
subtyp
w
r
result
four
subtyp
hbsag
includ
ayr
ayw
adr
adw
repres
phenotyp
express
hbv
genotyp
viral
particl
four
mrna
transcript
whose
function
known
longest
transcript
kb
templat
express
polymeras
precorecor
protein
also
genom
replic
second
longest
transcript
kb
code
hbsag
third
transcript
kb
code
hbsag
smallest
transcript
kb
encod
x
protein
core
gene
possess
precor
region
code
core
antigen
hbcag
cleavag
product
hbeag
e
antigen
transcript
precor
lead
cleavag
target
hbcag
endoplasm
reticulum
er
secret
hbeag
hbcag
integr
part
coreparticl
essenti
viral
packag
pre
gene
surfac
code
viral
envelop
essenti
hbv
attach
hepatocyt
hbv
viral
replic
known
proceed
three
stage
first
phase
dna
strand
synthes
complet
minu
strand
prior
synthesi
strand
second
phase
viru
polymeras
act
revers
transcriptas
final
phase
minu
strand
prime
end
termin
protein
plu
strand
prime
oligoribonucleotid
result
genom
viral
rna
hbv
bind
surfac
cell
follow
penetr
cell
viral
core
transport
nucleu
circular
viral
dna
convert
coval
close
circular
dna
cccdna
act
templat
synthesi
viral
rna
hbv
undergo
integr
normal
replic
seen
retrovirus
minu
strand
dna
synthesi
initi
short
direct
repeat
polymeras
primer
plu
strand
dna
synthesi
initi
continu
passag
end
minu
strand
lead
product
open
circular
dna
similar
matur
hbv
matur
core
particl
pack
hbsagpr
er
export
cell
nucleu
maintain
stabl
pool
cccdna
transport
freshli
synthes
dna
back
nucleu
figur
lamivudin
use
treatment
hbv
inhibit
viral
dna
synthesi
becom
incorpor
grow
dna
result
prematur
termin
chain
adefovir
dipivoxil
nucleotid
analogu
amp
adenosin
monophosph
prodrug
adefovir
use
treatment
hbv
inhibit
dna
polymeras
also
revers
transcriptas
activ
incorpor
viral
dna
result
chain
termin
entecavir
act
inhibit
hbv
replic
three
differ
stage
dna
polymeras
prime
negativestrand
dna
revers
transcript
positivestrand
dna
synthesi
entecavir
also
use
person
suffer
chronic
hepat
b
decompens
liver
diseas
telbivudin
lnucleosid
analogu
revers
transcriptas
inhibitor
anoth
drug
select
potent
antivir
activ
hepat
b
viru
figur
treatment
hiv
use
person
hepat
b
especi
resist
treatment
lamivudin
clevudin
pyrimidin
nucleosid
also
effect
inhibit
viral
replic
approv
south
korea
thymosin
thymicderiv
peptid
potenc
stimul
function
tcell
still
clinic
trial
figur
scheme
papillomavirus
first
discov
viral
particl
around
genotyp
identifi
later
papillomavirus
found
mammal
bird
reptil
like
turtl
mode
transmiss
clear
basal
layer
infect
seem
play
major
role
anogenit
human
papilloma
viru
hpv
infect
known
transmit
sexual
contact
hpv
nonenvelop
doublestrand
dna
virus
belong
famili
papillomavirida
known
infect
skin
mucos
surfac
epitheli
cell
viru
circular
genom
kb
encircl
protein
shell
made
major
minor
capsid
protein
seven
orf
open
read
frame
encod
viral
protein
six
earli
protein
earli
protein
encod
transcript
present
suprabas
basal
epitheli
cell
allow
viral
transcript
replic
protein
play
major
role
cell
transform
immort
orf
encrypt
viral
protein
shell
surfac
orf
encrypt
capsid
mass
play
major
role
viral
genom
encapsul
protein
also
help
assembl
structur
viruslik
particl
vlp
hpv
result
variou
cancer
genit
wart
especi
cervic
cancer
type
hpv
first
fdaapprov
test
identif
coba
hpv
test
followup
pap
test
treatment
hpv
includ
specif
antivir
therapi
except
presenc
lesion
two
vaccin
licens
unit
state
hpv
type
caus
cervic
cancer
respiratori
syncyti
viru
rsv
consid
major
pediatr
respiratori
pathogen
first
isol
chimpanze
caus
life
threaten
ill
first
month
rsv
place
genu
pneumoviru
belong
famili
paramyxovirida
rsv
extrem
contagi
least
half
infant
acquir
rsv
first
year
result
lower
respiratori
tract
diseas
lead
pneumonia
andor
bronchiol
ribavirin
synthet
nucleosid
approv
rsv
infect
known
interfer
mrna
express
palivizumab
synagi
human
monoclon
antibodi
anoth
drug
approv
fda
june
synagi
known
possess
fusion
neutral
inhibitori
activ
rsv
first
vaccin
treatment
rsv
develop
alumprecipit
formalininactiv
vaccin
figur
hepat
e
viru
hev
caus
organ
hepat
e
initi
term
nona
nonb
hepat
hev
recogn
year
major
caus
acut
hepat
worldwid
four
genotyp
hev
spread
develop
countri
apart
asia
major
concern
pregnant
women
lead
liver
diseas
hev
categor
genu
hepeviru
belong
famili
hepevirida
hepat
e
viral
genom
kb
size
three
orf
ci
element
play
major
role
hev
transcript
replic
encod
replicas
methyl
transferas
proteas
helicas
encod
protein
capsid
encod
protein
nondefin
function
natur
host
hev
human
anim
act
possibl
reservoir
amplif
viru
mode
transmiss
hev
could
transfus
specif
treatment
hev
infect
ribavirin
therapi
effect
person
although
contraind
pregnant
women
combin
ribavirin
also
use
chronic
infect
patient
sofosbuvir
report
easl
european
associ
studi
liver
meet
modest
inhibitor
hev
cultur
figur
scheme
dengu
dengu
hemorrhag
fever
dhf
arthropodborn
viral
infect
known
caus
four
viru
serotyp
den
belong
genu
flaviviru
peopl
dengu
endem
area
could
four
type
infect
lifetim
crossprotect
immun
provid
infect
one
serotyp
dengu
consid
urban
diseas
viru
complet
cycl
human
via
daybit
mosquito
aed
aegypti
first
pandem
dengu
occur
north
america
asia
africa
simultan
outbreak
seen
follow
global
pandem
world
war
ii
southeast
asia
geograph
distribut
multipl
viral
serotyp
expand
america
pacif
region
southeast
asia
epidem
lead
multipl
hospit
death
mani
countri
maldiv
india
sri
lanka
first
epidem
wherea
pakistan
epidem
although
dengu
erad
year
american
region
slowli
migrat
unit
state
dengu
start
emerg
worldwid
current
estim
million
peopl
risk
annual
viral
diseas
dengu
viru
denv
belong
genu
flaviviru
compris
virus
arthropodborn
infect
viru
lipid
envelop
inner
nucleocapsid
compris
singlestrand
rna
capsid
protein
viral
rna
transform
polyprotein
infect
cleav
structur
nonstructur
ns
protein
compon
matur
viral
particl
includ
envelop
e
structur
capsid
c
membran
thought
involv
viral
replic
figur
ns
protein
includ
express
host
cell
thought
play
role
viral
replic
function
complet
understood
cofactor
known
involv
process
viral
polyprotein
also
show
nucleotid
triphosphatas
rna
helicas
activ
hydrophob
protein
function
complet
understood
thought
involv
anchor
viral
replicas
protein
cell
membran
contribut
assembl
virion
play
role
cap
viral
rna
progeni
also
role
membran
alter
help
complex
format
viral
replicas
primari
vector
dengu
aed
aegypti
mosquito
transmiss
human
occur
bite
infect
femal
mosquito
incub
period
day
infect
mosquito
abil
transmit
viru
rest
insect
life
infect
human
serv
sourc
viru
uninfect
mosquito
could
transmit
infect
day
appear
first
symptom
occur
secondari
vector
spread
dengu
aed
albopictu
dengu
fever
denf
sever
flulik
infect
affect
adult
infant
young
children
lead
occasion
death
fever
usual
accompani
vomit
rash
sever
headach
joint
muscl
pain
pain
behind
eye
swollen
gland
symptom
last
day
follow
incub
period
dengu
becom
deadli
one
follow
symptom
occur
organ
impair
plasma
leak
respiratori
stress
fluid
accumul
sever
bleed
current
proper
treatment
vaccin
denf
case
sever
dengu
medic
practition
nurs
give
necessari
medic
care
maintain
volum
patient
bodi
fluid
sever
acut
respiratori
syndrom
sar
caus
coronaviru
could
term
atyp
pneumonia
first
identifi
china
guangdong
provinc
later
result
spread
mani
countri
coronavirus
belong
famili
includ
envelop
virus
replic
occur
hostcel
cytoplasm
includ
plu
sens
singlestrand
rna
tract
structur
follow
infect
viru
transform
polyprotein
cleav
proteas
releas
mani
nonstructur
protein
includ
atpas
helicas
hel
rnadepend
rna
polymeras
respons
viral
replic
protein
synthesi
figur
viral
membran
includ
major
protein
spike
membran
insert
er
golgi
compart
rna
plu
strand
accumul
nucleocapsid
protein
proteinrna
complex
associ
membran
protein
er
form
viral
particl
bud
er
lumen
viral
particl
migrat
golgi
complex
exit
cell
mean
exocytosi
fdaapprov
drug
treatment
sar
although
drug
like
ribavirin
consid
proven
ineffect
prevent
sar
viral
growth
inhibit
literatur
also
show
combin
therapi
lopinavir
ritonavir
treatment
sar
thought
reduc
viral
load
norovirus
belong
famili
calicivirida
deriv
calyx
mean
cup
greek
genu
noroviru
discov
year
previous
call
norwalklik
virus
like
virus
viru
also
singlestrand
plu
sens
rna
kb
includ
three
orf
known
encod
nonstructur
polyprotein
could
cleav
viral
proteas
protein
encod
major
minor
capsid
protein
respect
protein
involv
format
two
domain
shell
protrud
p
subdomain
involv
immun
recognit
cellular
interact
five
genotyp
norovirus
known
molecular
character
gi
gii
giv
found
human
giii
gv
strain
seen
cattl
mice
respect
norovirus
major
caus
organ
acut
gastroenter
common
genotyp
respons
mani
outbreak
worldwid
gii
primari
mode
transmiss
includ
either
oral
fecal
rout
common
rout
includ
wateror
foodborn
persontoperson
contact
human
thought
host
human
norovirus
viru
sustain
wide
rang
temperatur
exist
variou
food
item
includ
fruit
veget
raw
oyster
along
drink
water
norovirus
also
result
repeat
infect
undergo
mutat
result
evolut
novel
strain
infect
host
diseas
result
fever
wateri
diarrhea
vomit
along
symptom
myalgia
headach
chill
known
fdaapprov
antivir
agent
treatment
noroviru
gastroenter
except
oral
rehydr
electrolyt
fluid
antisecretori
antimotil
drug
use
adult
suffer
diarrhea
ribavirin
interferon
known
inhibit
norwalk
viral
replic
whose
therapeut
efficaci
need
evalu
rupintrivir
formerli
known
irrevers
inhibitor
possess
vitro
antivir
activ
picornavirus
known
display
antinoroviru
activ
favipiravir
also
known
current
advanc
clinic
develop
influenza
viru
consid
rdrp
inhibitor
noroviru
inhibit
viral
replic
suramin
naphthalen
sulfon
deriv
anoth
rdrp
inhibitor
known
inhibit
genom
replic
prevent
synthesi
viral
subgenom
rna
nucleosid
analogu
consid
potent
inhibitor
norovirusinduc
diarrhea
mortal
vitro
mous
model
middl
east
respiratori
syndrom
coronaviru
merscov
coronaviru
could
lead
sever
pulmonari
diseas
human
first
identifi
jeddah
saudi
arabia
septemb
patient
suffer
renal
failur
pneumonia
infect
known
link
geograph
middl
eastern
countri
like
saudi
arabia
unit
arab
emir
jordan
qatar
merscov
belong
subfamili
coronavirina
repres
new
speci
genu
betacoronaviru
current
includ
pipistrellu
bat
coronaviru
tylonycteri
bat
coronaviru
novel
viru
seem
relat
virus
belong
famili
nycterida
vespertilionida
includ
insectivor
african
european
bat
respect
infect
thought
zoonot
primarili
limit
transmiss
human
human
date
effect
antivir
merscov
emphasi
place
organ
support
renal
respiratori
failur
shown
inhibit
vitro
merscov
replic
action
vivo
unknown
west
nile
fever
mosquitoborn
viral
diseas
led
sporad
outbreak
equin
human
diseas
europ
largest
outbreak
occur
romania
near
bucharest
consid
major
arbovir
ill
europ
west
nile
viru
wnv
member
japanes
enceph
belong
genu
flaviviru
famili
flavivirida
viru
initi
isol
blood
febril
femal
uganda
year
west
nile
district
primari
vector
viru
includ
mosquito
predominantli
belong
genu
culex
primari
host
wild
bird
current
fdaapprov
drug
licens
vaccin
avail
treatment
wnv
adjuv
therapi
use
treatment
wnv
enceph
intraven
immunoglobulin
ivig
hepat
caus
hepat
viru
hdv
lead
sever
liver
diseas
hepat
uncommon
unit
state
gener
occur
coinfect
hepat
b
viru
hdv
hepatotrop
defect
viru
depend
hbv
envelop
provis
hdv
includ
hepat
b
surfac
antigen
hbsag
rna
genom
rodlik
circular
structur
possess
selflig
autocatalyt
cleavag
properti
rna
polymeras
ii
effect
rna
replic
protein
encod
hdvrna
hepat
antigen
hdag
whose
short
long
form
play
role
morphogenesi
replic
viru
treatment
avail
chronic
hepat
alpha
interferon
although
inhibit
hbv
result
decreas
hepat
viru
replic
hepat
complic
prevent
hepat
b
vaccin
hepat
caus
hepat
viru
hav
enteroviru
belong
famili
picornavirida
larg
epidem
hepat
occur
year
hav
singlemolecul
rna
surround
small
protein
capsid
nm
diamet
incub
period
day
chronic
infect
seen
hepat
common
mode
transmiss
persontoperson
contact
oral
ingest
major
rout
clinic
ill
could
protect
give
immun
globulin
incub
period
exposur
hav
certain
hepat
vaccin
also
effect
diseas
rotaviru
lead
caus
diarrhea
among
children
worldwid
viral
genom
includ
doublestrand
rna
enclos
threelay
viral
capsid
four
major
capsid
two
minor
coexpress
major
capsid
protein
differ
combin
result
product
stabl
viruslik
particl
vlp
respons
mainten
function
structur
characterist
matur
viral
particl
outer
layer
compos
glycoprotein
dimer
spike
respons
induc
neutral
antibodi
viral
hemagglutinin
inner
capsid
major
protein
constitut
known
possess
rna
polymeras
activ
core
part
includ
doublestrand
rna
segment
cover
coreprotein
mass
figur
rotaviru
known
infect
intestin
lead
diarrhea
could
last
day
treatment
rotaviru
infect
diseas
could
prevent
vaccin
sever
diseas
lie
dehydr
treat
fluid
varicellazost
viru
vzv
herpesviru
lead
chicken
pox
varicella
shingl
herp
zoster
viru
includ
nucleocapsid
encapsul
core
linear
doublestrand
dna
whose
arrang
done
short
long
uniqu
segment
orf
bp
tegument
made
protein
separ
capsid
lipid
envelop
lipid
envelop
incorpor
main
viral
glycoprotein
vzv
smallest
known
human
herpesviru
figur
peopl
infect
chicken
pox
prone
shingl
occur
age
risk
increas
grow
age
chicken
pox
develop
blister
rash
mean
viru
dormant
nerv
cell
reactiv
produc
shingl
travel
nerv
skin
inflamm
seen
nerv
lead
afterpain
term
postherpet
neuralgia
phn
could
chronic
sever
vzv
transmiss
occur
respiratori
rout
zostavax
vaccin
use
vzv
approv
fda
uslicens
vaccin
known
date
antivir
drug
approv
treatment
vzv
infect
includ
valacyclovir
acyclovir
famciclovir
replac
nucleosid
analogu
vidarabin
araa
acyclovir
valacyclovir
valin
ester
deriv
acyclovir
act
competit
inhibitor
result
chain
termin
viral
dna
polymeras
varizig
varicella
zoster
immun
globulin
approv
us
fda
decemb
orphan
drug
could
given
exposur
vzv
figur
scheme
genit
herp
sexual
transmit
diseas
std
caus
two
type
virus
herp
simplex
viru
type
type
highli
common
unit
state
transmiss
occur
anal
oral
vagin
sex
person
infect
diseas
herp
simplex
viru
hsv
largest
herp
viru
belong
famili
herpesvirida
virus
belong
famili
envelop
virus
includ
tegument
capsid
genom
viral
envelop
fragil
space
capsid
viral
envelop
call
tegument
usual
contain
glycoprotein
enzym
necessari
viral
replic
nucleocapsid
icosahedr
hexamer
pentamer
capsomer
doughnutshap
viral
genom
linear
doublestrand
dna
wrap
core
figur
similar
genom
structur
homolog
proteincod
homolog
sequenc
region
associ
oral
diseas
wherea
associ
genit
diseas
certain
part
world
subsaharan
africa
known
occur
childhood
sexual
transmit
contrast
base
anatom
site
respons
genit
herp
develop
countri
current
medic
treatment
hsv
infect
includ
antivir
agent
like
acyclovir
vidarabin
idoxuridin
ribavirin
phosphonoform
acyclovir
valyl
prodrug
form
known
valacyclovir
wide
use
acyclovir
purin
analogu
act
substrat
viral
thymidin
kinas
therebi
inhibit
viral
dna
polymeras
select
viral
resist
acyclovir
new
antivir
evolv
treatment
hsv
phosphonoform
deriv
phosphonoacet
acid
potent
inhibitor
hsv
dna
polymeras
scheme
figur
ebola
hemorrhag
fever
ebola
hf
viral
diseas
caus
ebola
viru
ebov
gain
import
review
due
current
ongo
outbreak
west
africa
along
guinea
liberia
uganda
sinc
march
report
show
around
death
case
report
guinea
case
sierra
leon
suspect
case
liberia
may
june
number
ebola
death
rais
sinc
decemb
death
liberia
death
sierra
leon
death
guinea
death
nigeria
death
mali
death
unit
state
first
human
outbreak
ebola
viru
record
follow
major
outbreak
gabon
republ
congo
ebov
nonseg
envelop
neg
strand
rna
viru
belong
famili
filovirida
four
speci
ebov
sudan
divoir
reston
zair
known
caus
diseas
human
zair
associ
highest
human
lethal
genom
consist
seven
gene
respons
synthesi
eight
protein
ebola
viru
enclos
membran
infect
cell
envelop
ebola
glycoprotein
inner
membran
support
layer
matrix
protein
possess
central
cylindr
nucleocapsid
necessari
storag
deliveri
rna
genom
ebola
glycoprotein
bind
cellsurfac
receptor
get
genom
insid
ebov
share
mani
featur
similar
hiv
envelop
glycoprotein
influenza
hemagglutinin
cover
carbohydr
chain
would
help
viru
hide
immun
system
viru
could
transform
differ
shape
bound
cell
surfac
drag
cell
viru
close
enough
caus
membran
fusion
matrix
protein
also
call
help
shape
bud
viru
protein
present
membran
help
make
connect
nucleocapsid
membran
nucleocapsid
present
center
viru
help
protect
viral
genom
howev
nucleoprotein
subunit
rigid
virus
show
wavi
structur
transcript
fourth
gene
lead
express
glycoprotein
transmembranelink
gp
secret
glycoprotein
sgp
gp
remain
key
target
design
entri
inhibitor
vaccin
gp
cleav
furin
posttransl
yield
subunit
disulfidelink
known
effect
attach
host
cell
facilit
fusion
host
viral
membran
figur
standard
treatment
ebov
hf
limit
support
therapi
includ
balanc
electrolyt
fluid
patient
maintain
blood
pressur
oxygen
suppli
treat
complic
infect
earli
symptom
ebov
hf
includ
fever
headach
difficult
diagnos
ebov
known
treatment
yet
avail
human
treatment
ebola
viru
although
mani
drug
avail
commerci
synthet
sourc
limit
includ
drug
resist
side
effect
cell
toxic
longterm
drug
treatment
possibl
explan
failur
previous
mention
antihiv
drug
addit
evolut
develop
nucleosid
antivir
reveal
tremend
potenti
marin
product
identif
novel
prototyp
also
reveal
necess
develop
drug
natur
resourc
marin
environ
marin
speci
cover
twothird
planet
make
signific
sourc
product
novel
compound
possibl
fewer
advers
effect
higher
inhibit
activ
compound
obtain
marin
sourc
discuss
follow
section
found
possess
activ
figur
phlorotannin
tannin
deriv
isol
brown
alga
biosynthes
polymer
phloroglucinol
monom
unit
acquir
pathway
acetatemalon
highli
watersolubl
compound
classifi
four
differ
categori
phlorotannin
contain
ether
linkag
fuhalol
phlorethol
phenyl
linkag
fucol
phenyl
ether
linkag
fucophloroethol
dibenzodioxin
linkag
eckol
figur
admet
predictor
show
diphlorethohydroxycarmalol
violat
three
criteria
lipinski
guidelin
compound
also
show
low
permeabl
tend
poor
permeat
cell
membran
base
polar
surfac
area
phloroglucinol
deriv
exhibit
cytotox
concentr
inhibit
replic
almost
entir
phloroglucinol
deriv
exhibit
inhibit
similar
flavonoid
block
interact
revers
transcriptas
rt
rna
templat
viral
entri
inhibitor
abovement
factor
like
permeabl
may
problem
could
consid
import
lead
compound
could
inhibit
viral
entri
current
synthes
fdaapprov
drug
could
inhibit
viru
variou
replic
stage
henc
abovement
limit
variou
compound
could
overcom
chang
rout
administr
use
intraven
subcutan
sc
instead
oral
tabl
chitin
wide
found
crustacean
fungi
invertebr
insect
longchain
polym
nacetylglucosamin
abundantli
seen
shell
shrimp
crab
chitosan
form
deacetyl
chitin
sulfat
deriv
chitin
chitosan
possess
activ
includ
antimicrobi
antioxid
other
ncarboxymethylchitosan
n
osulf
ncmc
deriv
ncarboxymethyl
chitosan
known
inhibit
transmiss
human
cell
inhibit
due
blockad
interact
glycoprotein
receptor
present
viral
coat
target
protein
present
lymphocyt
therebi
inhibit
revers
transcriptas
sulfat
posit
led
complet
inhibit
infect
tlymphocyt
concentr
without
cytotox
result
show
biolog
activ
sulfat
chitin
control
chang
sulfat
group
posit
chitosan
convert
chitooligosaccharid
improv
water
solubl
therefor
biolog
activ
low
molecular
weight
sulfat
chitooligosaccharid
scoss
known
possess
antihiv
activ
show
lytic
effect
inhibit
syncytia
format
median
effect
concentr
ec
valu
respect
antigen
product
could
suppress
ec
valu
bal
rf
respect
also
inhibit
viral
entri
cell
fusion
prevent
bond
hiv
surfac
receptor
figur
admet
predictor
show
sulfat
chitin
violat
three
criteria
lipinski
guidelin
wherea
chitosan
violat
four
criteria
addit
also
show
low
permeabl
low
flexibl
tendenc
permeat
cell
membran
howev
per
mechan
action
known
inhibit
viral
entri
fusion
permeabl
could
consid
limit
factor
scoss
inhibit
replic
bind
loop
therebi
interf
bind
possess
high
rate
intestin
absorpt
crucial
properti
drug
candid
main
drawback
chitosan
sulfat
oligosaccharid
deriv
high
anticoagul
activ
limit
sco
clinic
test
approv
infect
hiv
subject
limit
could
overcom
sar
structureact
relationship
studi
tri
variou
medicin
chemistri
alter
allevi
anticoagul
activ
tabl
sulfat
polysaccharid
macromolecul
chemic
anion
present
marin
alga
along
mammal
invertebr
although
marin
alga
major
sourc
also
possess
along
anticanc
anticoagul
activ
figur
sp
sulfat
polysaccharid
prevent
viru
attach
target
molecul
cell
surfac
sp
possess
bind
site
rel
similar
bind
region
henc
bind
lymphocyt
sp
inhibit
bind
monoclon
antibodi
initi
two
domain
therebi
disrupt
interact
antihiv
activ
sp
shield
posit
charg
site
loop
protein
therebi
prevent
viru
attach
cell
surfac
sp
red
alga
also
known
possess
activ
schizymenia
dubyi
red
alga
produc
sulfat
glucuronogalactan
known
possess
activ
polysaccharid
suppress
syncyti
format
complet
concentr
also
inhibit
revers
transcriptas
low
concentr
without
cytotox
cell
mechan
action
involv
inhibit
attach
viru
host
cell
nakashima
et
al
prepar
extract
citrat
buffer
sea
algal
extract
sae
marin
red
alga
schizymenia
pacif
ica
show
inhibit
hiv
replic
hiv
revers
transcriptas
sae
sulfat
polysaccharid
molecular
weight
belong
famili
includ
sulfon
galactos
sulfat
residu
respons
inhibit
hiv
revers
transcriptas
inhibitori
dose
iuml
brown
alga
also
known
produc
sp
activ
via
differ
mechan
action
fucan
present
mainli
brown
alga
high
molecular
weight
possess
repeat
chain
sulfat
fucos
fucan
deriv
seawe
speci
lobophora
varieg
spatoglossum
schroederi
fucu
vesiculosu
dictyota
mertensii
inhibit
revers
transcriptas
galactofucan
fraction
l
varieg
show
revers
transcriptas
inhibit
concentr
synthet
polynucleotid
inhibit
fucan
mertensii
schroederi
display
inhibit
activ
revers
transcriptas
enzym
mgml
inhibit
respect
fucan
b
schroederi
show
inhibit
activ
concentr
fucan
fraction
f
vesiculosu
show
high
inhibit
activ
revers
transcriptas
enzym
concentr
similarli
fraction
galactofucan
adenocysti
utriculari
also
present
activ
block
prior
event
viru
replic
display
strong
inhibit
activ
replic
low
ic
valu
respect
sp
also
produc
microalga
naviculan
one
exampl
isol
navicula
directa
possess
activ
demonstr
inhibitori
effect
format
cellcel
fusion
hela
cell
hiv
ic
valu
new
type
dgalactan
sulfat
isol
meretrix
petechiali
clam
possess
activ
inhibit
syncytia
format
concentr
inhibit
laminaran
also
term
laminarin
watersolubl
polysaccharid
includ
glucos
unit
possess
branch
isol
brown
alga
laminaran
along
laminaran
polysaccharid
prepar
kelp
known
inhibit
hiv
revers
transcriptas
adsorpt
concentr
suggest
good
inhibit
hiv
replic
figur
galactan
sulfat
gs
polysaccharid
isol
agardhiella
tenera
red
seawe
show
activ
ic
valu
respect
gs
prevent
bind
cell
along
bind
mab
also
known
activ
envelop
virus
includ
togavirus
arenavirus
herpesvirus
other
carrageenan
extract
mainli
certain
genera
red
seawe
includ
hypnea
eucheuma
gigartina
chondru
yamada
cowork
report
antihiv
activ
oacyl
carrageenan
polysaccharid
variou
molecular
weight
mean
sulfat
depolymer
calcium
spirulan
casp
sulfat
polysaccharid
isol
marin
bluegreen
alga
arthrospira
platensi
show
potent
activ
ic
valu
reduc
viral
replic
ed
valu
casp
also
known
inhibit
viral
replic
virus
includ
hcmv
measl
polio
coxsacki
viru
prevent
penetr
viru
host
cell
xin
et
al
report
marin
polysaccharid
deriv
algin
inhibit
hiv
replic
vivo
vitro
attribut
inhibit
viral
revers
transcriptas
interf
viral
adsorpt
enhanc
immun
function
woo
et
al
report
inhibitori
effect
marin
shellfish
polysaccharid
seven
differ
shellfish
includ
meretrix
lusoria
meretrix
petechiali
ruditap
philippinarum
sinonovacula
constricta
lamark
scapharca
subcrenata
scapharca
broughtonii
mytilu
coruscu
vitro
inhibit
viral
fusion
protein
tlymphocyt
surfac
sp
effect
inhibit
cellcel
adhes
studi
prove
sp
could
use
antivir
vagin
formul
disturb
function
epitheli
cell
vagina
normal
bacteri
flora
lectin
protein
bind
carbohydr
present
prokaryot
alga
fungi
plant
coral
vertebr
invertebr
specif
differ
glycan
structur
henc
bind
glycan
present
molecul
hiv
envelop
result
inhibit
viral
cell
fusion
hiv
infect
syncytium
format
sever
differ
lectin
like
griffithsin
grft
obtain
red
alga
grif
fithsia
sp
report
possess
activ
lectin
possess
common
amino
acid
along
unusu
one
posit
cytopath
effect
produc
laboratori
strain
clinic
primari
isol
tlymphoblast
cell
inhibit
concentr
low
grft
block
celltocel
fusion
uninfect
infect
cell
also
prevent
bind
glycoprotein
monoclon
antibodi
recent
year
marin
invertebr
becom
new
sourc
unusu
lectin
one
exampl
cvl
specif
lectin
isol
chaetopteru
variopedatu
marin
worm
inhibit
cytopath
effect
caus
viral
antigen
product
ec
valu
respect
ec
valu
cvl
caus
blockad
infect
uninfect
celltocel
fusion
process
concentr
cvl
exhibit
inhibit
respect
entri
host
cell
anoth
lectin
cgl
isol
c
grayanu
mussel
present
high
affin
mucin
type
glycoprotein
two
lectin
dtl
dtla
isol
ascidium
ternatanum
similarli
isol
marin
worm
serpula
vermiculari
calcium
ca
independ
lectin
shown
possess
activ
bioactiv
peptid
wide
isol
marin
organ
mean
enzymat
hydrolysi
report
mani
marin
bioactiv
peptid
activ
oyster
possess
antivir
antibacteri
substanc
prevent
infecti
diseas
henc
larg
isol
effort
made
discov
proteas
inhibit
substanc
oyster
crassostrea
giga
yield
two
peptid
leuleuglutyrseril
leuleuglutyrserleu
exhibit
strong
inhibit
proteas
ic
valu
respect
inhibitori
activ
found
relat
length
amino
acid
sequenc
presenc
c
ntermin
hydrophob
amino
acid
figur
cyanovirinn
cvn
isol
cyanobacterium
nostoc
ellipsosporum
antivir
peptid
molecular
weight
kda
inhibitori
effect
low
nanomolar
concentr
cvn
prevent
transmiss
hiv
infect
uninfect
cell
prevent
celltocel
fusion
peptid
polyphemusin
ii
tachyplesin
iii
isol
hemocyt
debri
horsesho
crab
limulu
polyphemu
tachypleu
tridentatu
found
inhibit
hiv
cell
fusion
mani
synthet
peptid
analogu
prepar
synthet
peptid
analogu
polyphemusin
ii
show
strongest
antihiv
activ
low
vitro
cytotox
ec
valu
compar
less
azidothymidin
figur
macrolactina
antivir
compound
isol
marin
bacteria
includ
ring
lacton
openchain
acid
relat
glucos
inhibit
hiv
replic
concentr
diterpen
isol
dictyota
menstruali
marin
alga
inhibit
replic
viru
ec
valu
respect
diterpen
affect
viral
intern
viral
attach
instead
inhibit
hiv
revers
transcriptas
ic
valu
respect
figur
antivir
equisetin
phomasetin
isol
marin
fungi
fusarium
heterosporum
phoma
sp
show
inhibit
integras
ic
rang
figur
thalassiolin
ac
isol
caribbean
sea
grass
thalassia
testudinum
sulfat
flavon
glycosid
inhibit
hiv
replic
ic
target
integrasecatalyz
strand
transfer
ic
thalassiolin
ac
show
potenc
hiv
integras
due
presenc
sulfat
glucos
function
figur
didemnaket
b
isol
ascidian
didemnum
sp
shown
inhibit
hivproteas
ic
valu
respect
cyclodidemniserinol
trisulf
isol
extract
palauan
ascidian
didemnum
guttatum
show
inhibit
hivintegras
ic
figur
lamellarin
first
isol
prosobranch
mollusk
belong
genu
lamellaria
lamellarin
isol
arabian
sea
ascidian
shown
inhibit
hivintegras
lamellarin
inhibit
strandtransf
activ
ic
integras
termin
cleavag
activ
ic
figur
spong
histor
produc
promis
drug
lead
drug
obtain
spong
use
treatment
hiv
also
hsv
exampl
compound
isol
spong
use
treatment
discuss
detail
follow
section
avarol
first
isol
marin
spong
disidea
avara
avaron
synthes
silver
oxid
oxid
avarol
structur
rearrang
gogineni
driman
skeleton
show
inhibitori
effect
replic
aid
htlv
iiibinfect
human
cell
mechan
involv
blockad
gag
protein
viral
infect
therebi
prevent
replic
viru
explor
mechan
action
avarol
shown
block
trna
requir
glutamin
synthesi
play
vital
role
synthesi
viral
proteas
necessari
replic
figur
admet
predictor
show
avarol
violat
one
criterion
lipinski
guidelin
avaron
violat
carbonyl
group
quinon
ring
includ
hydroxyl
group
ortho
posit
known
respons
blockad
revers
transcriptas
activ
henc
may
like
good
candid
consid
vivo
studi
limit
minor
tabl
curcuphenol
isoquinolin
deriv
previous
patent
treatment
activ
inhibit
revers
transcriptas
enzym
proteas
enzym
viral
entri
inhibit
wherea
indol
alkaloid
act
revers
transcriptas
inhibitor
activ
known
increas
indol
substitut
henc
analogu
show
activ
due
presenc
one
abovement
moieti
activ
shown
improv
alkyl
indol
nitrogen
seen
analogu
j
figur
admet
predictor
show
curcuphenol
analogu
violat
one
criterion
lipinski
guidelin
henc
may
consid
potenti
candid
synthes
compar
fdaapprov
drug
like
saquinavir
fosamprenavir
violat
one
criterion
limit
less
case
tabl
papuamid
isol
marin
spong
theonella
swinhoei
theonella
mirabili
known
possess
cytotox
effect
papuamid
b
isol
spong
mirabili
exhibit
activ
concentr
papuamid
b
c
isol
swinhoei
figur
papuamid
membranetarget
mechan
mechan
action
shown
respons
virucid
activ
mechan
action
involv
inhibit
hiv
pseudotyp
virus
express
glycoprotein
envelop
amphotrop
murin
leukemia
viru
vesicular
stomat
viru
suggest
entri
inhibit
envelop
glycoprotein
specif
inhibit
viru
initi
stage
viral
replic
cycl
target
viru
cell
henc
exhibit
direct
virucid
mechan
papuamid
b
target
phospholipid
phosphatidylserin
ps
present
viru
papuamid
c
also
inhibit
viral
entri
figur
admet
predictor
show
papuamid
b
c
violat
three
criteria
lipinski
guidelin
also
show
low
flexibl
possess
tendenc
permeat
cell
membran
addit
peptidederiv
drug
must
administ
iv
could
overcom
permeabl
limit
also
repres
potenti
challeng
molecul
tabl
callipeltin
isol
spong
belong
genu
callipelta
also
possess
activ
cytopath
effect
inhibit
median
effect
dose
ed
valu
similarli
neamphamid
isol
neamphiu
huxleyi
possess
cytoprotect
activ
infect
ec
valu
certain
mirabamid
inhibit
fusion
isol
spong
siliquariaspongia
mirabili
among
mirabamid
shown
activ
fusion
assay
neutral
ic
valu
respect
mirabamid
shown
select
inhibit
membran
fusion
level
figur
admet
predictor
show
callipeltin
mirabamid
celebesid
violat
three
criteria
lipinski
guidelin
wherea
neamphamid
theopapuamid
b
violat
four
criteria
addit
also
show
low
permeabl
low
flexibl
tendenc
permeat
cell
membran
abovement
compound
belong
class
depsipeptid
mechan
action
similar
papuamid
limit
could
overcom
similar
peptid
rout
administr
intraven
limit
permeat
factor
tabl
microspinosamid
isol
indonesian
spong
sidonop
microspinosa
peptid
contain
amino
acid
residu
organ
aqueou
extract
show
activ
show
activ
concentr
homophymin
new
compound
isol
homophymia
sp
possess
cytoprotect
activ
infect
ic
valu
figur
admet
predictor
show
microspinosamid
violat
three
criteria
lipinski
guidelin
addit
also
show
low
permeabl
low
flexibl
low
tendenc
permeat
cell
membran
howev
interest
fact
microspinosamid
structur
could
incorpor
amino
acid
residu
along
numer
uncommon
amino
acid
first
natur
peptid
includ
residu
henc
alway
challeng
develop
molecul
author
manuscript
author
manuscript
differ
techniqu
adopt
synthes
compound
reduc
limit
tabl
dragmacidin
f
new
bromoindol
alkaloid
isol
spong
belong
genu
halicortex
southern
coast
ustica
island
itali
show
vitro
activ
ec
valu
respect
compound
known
inhibit
syncytia
format
later
infect
without
caus
direct
toxic
cell
figur
admet
predictor
show
dragmacidin
f
violat
two
criteria
lipinski
guidelin
addit
also
possess
low
tendenc
permeat
cell
membran
direct
toxic
involv
cell
use
compound
side
effect
could
reduc
extent
fosamprenavir
fdaapprov
drug
tabl
also
violat
one
criterion
lipinski
guidelin
henc
limit
factor
dragmacidin
f
avoid
consid
develop
bring
clinic
trial
tabl
manzamin
isol
haliclona
sp
uniqu
complex
polycycl
ring
system
coupl
moieti
known
possess
antiparasit
antimicrobi
biolog
activ
manzamin
x
neokauluamin
also
show
activ
ec
valu
respect
figur
admet
predictor
indic
manzamin
violat
two
criteria
lipinski
guidelin
compound
show
low
metabol
clearanc
good
oral
bioavail
long
halflif
oral
iv
pharmacokinet
studi
conduct
rat
manzamin
good
acid
solubl
suggest
readili
dissolv
stomach
henc
could
consid
potenti
good
candid
clinic
assess
develop
tabl
manadomanzamin
b
isol
indonesian
spong
acanthostrongylophora
sp
manadomanzamin
b
xestomanzamin
show
activ
ec
valu
respect
also
exhibit
activ
aid
opportunist
fungal
infect
figur
admet
predictor
show
manadomanzamin
b
violat
two
criteria
lipinski
guidelin
wherea
xestomanzamin
violat
criteria
structur
manadomanzamin
b
unpreced
rearrang
skeleton
manzamin
henc
compound
could
consid
similar
manzamin
could
dealt
accordingli
tabl
batzelladin
ae
also
known
possess
activ
isol
spong
belong
batzella
monanchora
genera
known
first
smallmolecularweight
entri
inhibitor
shown
inhibit
interact
crambescidin
isol
starfish
spong
genu
group
batzella
monanchora
show
similar
activ
inhibit
envelopemedi
fusion
along
fromiamycalin
isol
starfish
synthet
batzelladin
analogu
crambescidin
activ
ec
valu
similarli
ptilomycalin
isol
spong
monanchora
unguifera
starfish
also
known
exhibit
activ
ec
valu
meanwhil
batzelladin
c
show
inhibit
ec
compar
batzelladin
ptilomycalin
show
potent
activ
aid
opportunist
infect
figur
admet
predictor
show
ptilomycalin
crambescidin
violat
three
criteria
lipinski
guidelin
wherea
batzelladin
c
violat
addit
ptilomycalin
show
low
flexibl
low
tendenc
permeat
cell
membran
wherea
crambescidin
exhibit
low
permeabl
low
flexibl
less
tendenc
permeat
cell
membran
batzelladin
c
show
low
permeabl
less
flexibl
compound
entri
inhibitor
limit
permeabl
consid
seriou
issu
one
rather
concentr
improv
limit
develop
tabl
isoaaptamin
aaptamin
isol
variou
spong
belong
suberit
hymenlacidon
aapto
genera
known
possess
activ
concentr
respect
potenc
activ
explor
sar
fluorin
substitut
indol
heterocycl
system
figur
admet
predictor
predict
isoaaptamin
aaptamin
violat
lipinski
guidelin
could
good
indic
might
involv
potenti
side
effect
problem
perhap
could
consid
potenti
candid
develop
tabl
petrosin
four
cyanthiwigin
isol
epipolasi
reiswigi
jamaican
spong
includ
cyanthiwigin
b
c
among
cyanthiwigin
b
known
possess
moder
activ
ec
valu
may
due
keton
group
present
cyanthiwigin
b
absent
three
compound
figur
admet
predictor
show
cyanthiwigin
b
violat
lipinski
guidelin
structur
look
simpl
prepar
limit
could
anoth
like
candid
consid
preclin
trial
develop
tabl
two
sulfat
sterol
isol
speci
xestospongia
unidentifi
haplosclerid
spong
known
possess
unusu
steroid
sulfam
estershaplosam
b
show
inhibit
toward
integras
ic
valu
respect
sulfam
group
present
haplosam
respons
inhibit
integras
figur
clathsterol
activ
novel
sulfat
sterol
isol
red
sea
spong
clathria
sp
show
inhibit
revers
transcriptas
figur
polyacetylenetriol
pat
isol
marin
spong
petrosia
sp
show
select
inhibit
dnaand
rnadepend
dna
polymeras
activ
retrovir
revers
transcriptas
ic
valu
pat
consid
revers
noncompetit
inhibitor
known
interfer
catalyt
step
viral
dna
polymer
figur
new
furanoterpen
isol
madagascan
spong
lendenfeldia
design
dehydrofurodendin
show
inhibit
revers
transcriptas
associ
dnaand
rnadirect
dna
polymeras
ic
valu
rang
figur
cimino
et
al
report
new
antihiv
polysaccharid
name
rosacelos
compris
glucos
fucos
sulfat
isol
aqueou
extract
marin
spong
mixylla
rosacea
possess
linear
polysaccharid
structur
compris
residu
molar
ratio
figur
tabl
show
summari
marin
antivir
possess
activ
marin
polysaccharid
isol
algin
known
prevent
replic
hepat
b
viru
hbv
inhibit
activ
hbv
dnapolymeras
improv
hostcel
immun
function
wu
et
al
report
dna
replic
duck
hbv
could
inhibit
oyster
polysaccharid
reduc
duck
hbvdna
content
serum
thu
show
antihbv
vivo
effect
guan
identifi
polymer
mannuron
acid
sulfat
could
effect
reduc
antigen
level
dna
level
hbv
duck
blood
thu
improv
cellular
humor
immun
function
replic
hbv
also
known
indirectli
inhibit
sulfat
polymannuroguluron
spmg
isol
brown
alga
improv
cellular
humor
immun
function
figur
discorhabdin
c
dihydrodiscorhabdin
c
isol
latrunculia
genu
alaskan
spong
speci
exhibit
antihcv
activ
ec
concentr
figur
buck
et
al
establish
carrageenan
could
inhibit
hpv
infect
process
antivir
effect
known
better
isol
eucheuma
denticulatum
compar
carrageenan
bind
hpv
capsid
inhibit
viral
adsorpt
process
along
viralentri
viralunco
process
mechan
involv
inhibit
hpv
known
independ
heparin
sulfat
viral
adsorpt
figur
extracellular
sulfat
polysaccharid
isol
marin
microalga
cochlodinium
polykrikoid
known
inhibit
cytopath
effect
influenza
viru
iav
type
b
activ
sulfat
calyceramid
ac
isol
marin
spong
discodermia
calyx
known
inhibit
iav
neuraminidas
inhibitor
calyceramid
ac
known
inhibit
neuraminidas
clostridium
perf
ringen
ic
valu
respect
figur
weinbersterol
b
isol
spong
petrosia
weinbergi
known
inhibit
mous
influenza
viru
novel
terpenoid
stachyflin
isol
fungu
stachybotri
sp
known
inhibit
influenza
viru
inhibitori
concentr
known
better
drug
zanamivir
amantadin
stachyflin
possess
novel
cisfus
decalin
along
pentacycl
moieti
known
exhibit
antivir
activ
inhibit
viral
hostcel
membran
envelop
figur
tang
et
al
show
lowmolecularweight
mw
carrageenan
along
deriv
exhibit
signific
inhibit
activ
influenza
viru
mice
pulmonari
edema
figur
report
antiiav
activ
dextran
sulfat
inhibit
iav
fusion
cell
membran
suppress
viral
replic
vivo
ivanova
et
al
report
inhibitori
effect
iav
ulvan
polysaccharid
isol
green
alga
whose
effect
known
strainspecif
dosedepend
akamatsu
et
al
report
new
type
fucos
polysaccharid
isol
brown
seawe
known
possess
excel
antiiav
effect
vitro
vivo
zhang
et
al
report
inhibit
activ
marin
polysaccharid
isol
perna
viridi
replic
iav
mdck
cell
addit
effect
ribavirin
antiiav
action
suggest
investig
marin
polysaccharid
antiiav
agent
figur
lowmolecularweight
kda
oligomer
mannuron
acid
om
oligosaccharid
deriv
polymannuron
acid
polysaccharid
show
good
activ
influenza
viru
vitro
vivo
guan
report
anoth
polymannuron
acid
deriv
polymannuron
acid
propyl
sulfat
pm
prepar
propyl
modif
sulfat
polymannuron
acid
polysaccharid
show
inhibitori
effect
neuraminidas
activ
iav
along
allevi
pneumonia
symptom
effect
caus
influenza
viral
infect
reduc
mortal
rate
mice
figur
kim
et
al
report
sulfat
polysaccharid
isol
marin
microalga
gyrodinium
impudium
show
maximum
inhibit
activ
iav
infect
target
viral
intern
adsorpt
prevent
viral
replic
wang
et
al
report
lowmolecularweight
oligosaccharid
known
effect
inhibit
iav
replic
vitro
vivo
also
note
carrageenan
oligosaccharid
could
enter
host
cell
inhibit
protein
translat
mrna
transcript
intern
therebi
prevent
viral
replic
figur
isol
two
extracellular
sulfat
polysaccharid
cochlodinium
polykrikoid
report
hasui
et
al
show
inhibit
cytopath
effect
rsv
type
b
grow
cell
fucan
polysaccharid
fucoidan
isol
cladosiphon
okamuranu
compris
sulfat
fucos
unit
glucuron
acid
show
inhibit
cell
littl
effect
three
type
talarico
cowork
report
interfer
intern
adsorpt
host
cell
mechan
involv
inhibit
thought
due
interfer
carrageenan
subsequ
uncoat
releas
denv
endosom
exhibit
inhibit
direct
interact
viral
membran
glycoprotein
e
ge
talarico
et
al
found
exhibit
inhibit
denv
replic
mammalian
mosquito
cell
affect
potenti
target
within
denv
host
cell
figur
two
novel
exopolysaccharid
isol
marin
bacteria
geobacillu
thermodenitrif
ican
bacillu
licheniformi
respect
known
inhibit
replic
extracellular
sulfat
polysaccharid
isol
marin
microalga
cochlodinium
polykrikoid
show
activ
fucoidan
sulfat
polysaccharid
isol
fucu
vesiculosu
brown
seawe
known
inhibit
replic
virus
calciumspirulan
casp
sulfat
polysaccharid
isol
arthrospira
platensi
marin
bluegreen
alga
also
known
inhibit
replic
influenzaa
naviculan
isol
navicula
directa
sulfat
polysaccharid
inhibit
earli
viral
replic
stage
ic
valu
rang
ed
nm
mechan
action
yet
known
thought
due
membran
destabil
figur
eudistomin
relat
alkaloid
isol
tunic
eudistoma
olivaceum
show
inhibit
didemnin
isol
trididemnum
sp
tunic
cyclic
depsipeptid
show
vivo
vitro
antivir
activ
figur
studi
indic
use
heparin
polysaccharid
lowmolecularweight
heparin
natur
inhibitor
requir
uniqu
sulfat
moieti
marin
heparinoid
polysaccharid
consid
structur
similar
heparin
possess
glycosaminoglycan
gag
like
biolog
properti
includ
ulvan
algin
sulfat
deriv
along
chitosan
sulfat
dextran
sulfat
recent
studi
indic
cellsurfac
heparinoid
sulfat
proteoglycan
initi
receptor
heparinoid
polysaccharid
known
prevent
viral
bind
cell
surfac
interact
posit
charg
region
cellsurfac
glycoprotein
figur
yu
et
al
studi
inhibitori
action
scallop
skirt
gag
ssgag
variou
concentr
signific
vitro
effect
antivir
effect
ssgag
known
increas
gradual
prolong
durat
action
carlucci
et
al
identifi
firm
bind
hsv
lead
virion
inactiv
therebi
inhibit
hsv
replic
studi
also
suggest
structur
chang
hsvglycoprotein
gb
gc
carrageenan
also
note
cycliz
isol
gigartina
skottsbergii
also
show
potent
antivir
effect
viraladsorpt
stage
figur
gogineni
et
al
harden
et
al
also
report
direct
inactiv
carrageenan
polysaccharid
isol
red
alga
low
concentr
virucid
activ
carrageenan
polysaccharid
known
increas
increas
molecular
weight
kda
direct
virucid
activ
carrageenan
known
due
format
stabl
carrageenanvirion
complex
make
bind
irrevers
fill
viral
envelop
site
necessari
viral
attach
host
cell
sulfat
polysaccharid
prevent
complet
viral
infect
process
also
known
tenofovir
alafenamid
fumar
taf
prodrug
patent
gilead
belong
nrti
current
phase
iii
clinic
trial
known
inhibit
revers
transcriptas
enzym
therebi
prevent
viral
replic
also
known
prodrug
tenofovir
anoth
drug
current
phase
ii
clinic
trial
patent
sequoia
pharmaceut
drug
boost
agent
antivir
properti
enhanc
level
second
drug
taken
investig
nnrti
treatment
name
dpc
dpc
quinazolinon
deriv
efavirenz
bristolmy
squibb
never
develop
potent
molecul
entri
inhibitor
investig
includ
pro
schere
c
pro
could
classifi
inhibitor
show
activ
viral
isol
bind
viral
schere
c
schc
belong
class
chemokin
receptor
inhibitor
oral
bioavail
synthet
peptid
belong
class
hiv
fusion
inhibitor
deriv
investig
hiv
integras
inhibitor
show
antiretrovir
activ
amino
acid
substitut
activ
site
integras
oral
bioavail
current
undergo
phase
iii
clinic
studi
investig
oral
hiv
nnrti
current
undergo
phase
ii
clinic
trial
merck
co
inc
also
known
cabotegravir
hiv
integras
inhibitor
ongo
phase
ii
clinic
trial
glaxosmithklin
figur
mericitabin
also
known
mcb
bioconvert
nucleotid
triphosph
hcv
nucleosid
inhibitor
rnadepend
rna
polymeras
studi
phase
ii
clinic
trial
found
potent
sofosbuvir
develop
roch
us
europ
danoprevir
macrocycl
peptidomimet
compound
inhibit
hcv
proteas
current
phase
ii
clinic
trial
manag
roch
setrobuvir
anoth
hcv
nonnucleosid
inhibitor
inhibit
rna
polymeras
bi
oral
hcv
proteas
inhibitor
stop
phase
iii
clinic
trial
manag
boehringeringelheim
similarli
bi
deleobuvir
oral
hcv
rnadepend
polymeras
inhibitor
undergo
phase
ii
clinic
trial
merck
co
two
hcv
drug
oral
proteas
inhibitor
romark
laboratori
develop
nitazoxanid
thiazolid
agent
treatment
viral
gastroenter
conduct
doubleblind
placebocontrol
clinic
trial
evalu
activ
noroviru
adenoviru
rotaviru
nitazoxanid
known
interfer
enzymedepend
transfer
reaction
pyruv
ferredoxin
oxidoreductas
pfor
necessari
anaerob
energi
metabol
prevent
synthesi
viral
protein
figur
roch
develop
human
monoclon
antibodi
design
neutral
influenza
viru
wide
rang
strain
bind
epitop
influenza
hemagglutinin
stalk
region
highli
conserv
current
phase
ii
clinic
trial
glaxosmithklin
develop
relenza
zanamivir
neuraminidas
inhibitor
treatment
influenza
current
phase
iii
clinic
trial
nitazoxanid
broadspectrum
antivir
phase
iii
clinic
trial
treatment
influenza
gilead
develop
fusion
inhibitor
treatment
respiratori
syncyti
viru
rsv
current
phase
ii
clinic
trial
block
rsv
replic
inhibit
rsv
fmediat
fusion
viral
rna
glaxosmithklin
develop
pediatr
recombin
viral
vector
vaccin
treatment
rsv
current
phase
clinic
trial
merck
co
develop
herp
zoster
inactiv
vzv
vaccin
evalu
prevent
herp
zoster
hz
hzrelat
complic
immunocompromis
subject
current
phase
iii
clinic
trial
natur
product
continu
provid
excel
sourc
new
lead
develop
antihiv
agent
summari
marin
organ
possess
activ
antivir
activ
shown
tabl
per
lipinski
guidelin
lipinski
rule
five
state
compound
molecular
weight
log
p
valu
hydrogen
bond
donor
hydrogen
bond
acceptor
oral
bioavail
better
absorpt
howev
oral
drug
formul
avail
market
fail
least
one
lipinski
guidelin
exampl
includ
didanosin
exce
log
p
valu
yet
avail
chewabl
tablet
zalcitabin
rare
use
treatment
hiv
also
fail
one
lipinski
guidelin
exceed
log
p
valu
avail
tablet
form
mani
exampl
see
tabl
absorpt
criteria
mention
support
inform
follow
mani
fdaapprov
drug
drug
fail
least
two
three
criteria
yet
consid
drug
favor
treat
similarli
compound
isol
marin
sourc
differ
kind
drug
compound
could
synthes
oral
formul
inexpens
formul
base
structur
includ
avarol
curcuphenol
analogu
c
j
r
manzamin
manadomanzamin
b
xestomanzamin
crambescidin
ptilomycalin
batzelladin
c
isoaaptamin
aaptamin
cyanthiwigin
b
could
consid
synthes
treatment
could
said
case
distribut
metabol
toxic
criteria
see
support
inform
inform
discuss
predict
admet
predictor
henc
drug
isol
marin
sourc
need
undergo
vivo
assay
advanc
toxicolog
evalu
clinic
trial
strengthen
result
valid
safeti
efficaci
profil
although
drug
fail
mani
criteria
could
still
adjust
alter
better
treat
diseas
progress
could
made
compound
marin
sourc
undergo
test
assay
major
challeng
involv
natur
product
drug
develop
drug
resist
long
drugdevelop
process
sometim
toxic
side
effect
mani
spongederiv
compound
shown
toxic
effect
could
potenti
solv
appli
biochem
technolog
combinatori
biosynthesi
synthet
biolog
metabol
engin
medicin
chemistri
postgenom
techniqu
viru
becom
resist
one
drug
possibl
treat
viru
natur
occur
deriv
similar
activ
viru
discoveri
new
drug
differ
deriv
belong
common
class
synthes
multipl
organ
could
solut
identifi
clone
modifi
gene
express
use
synthet
biolog
techniqu
use
combat
largescal
product
problem
therefor
understand
biolog
natur
live
condit
affect
growth
metabolit
product
spong
necessari
refer
web
version
pubm
central
supplementari
materi
isol
structur
determin
synthet
optim
marineterrestri
natur
product
toxin
focu
plant
invertebr
microbiom
group
current
work
preclin
develop
small
pipelin
natur
product
activ
infecti
diseas
cancer
neuropsychiatr
disord
crystal
structur
hiv
revers
transcriptas
integras
rna
polymeras
proteas
nnrti
use
treatment
hiv
includ
rilpivirin
etravirin
efavirenz
delavirdin
gogineni
et
al
